Exact Mass: 1056.5314346

Exact Mass Matches: 1056.5314346

Found 48 metabolites which its exact mass value is equals to given mass value 1056.5314346, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PIP(20:2(11Z,14Z)/6 keto-PGF1alpha)

{[(1S,6R,15S,16S,18R,19S,20R,21R,22R,23S,24R)-3,16,18,20,22,23,24-heptahydroxy-19-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-{[(11Z,14Z)-icosa-11,14-dienoyloxy]methyl}-3,8,13-trioxo-2,4,7-trioxa-3lambda5-phosphabicyclo[13.6.3]tetracosan-21-yl]oxy}phosphonic acid

C49H86O20P2 (1056.5187415999999)


PIP(20:2(11Z,14Z)/6 keto-PGF1alpha) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:2(11Z,14Z)/6 keto-PGF1alpha), in particular, consists of one chain of 11Z,14Z-eicosadienoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(6 keto-PGF1alpha/20:2(11Z,14Z))

{[(1S,6R,16S,17S,19R,20S,21R,22R,23R,24S,25R)-3,17,19,21,23,24,25-heptahydroxy-20-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-[(11Z,14Z)-icosa-11,14-dienoyloxy]-3,9,14-trioxo-2,4,8-trioxa-3lambda5-phosphabicyclo[14.6.3]pentacosan-22-yl]oxy}phosphonic acid

C49H86O20P2 (1056.5187415999999)


PIP(6 keto-PGF1alpha/20:2(11Z,14Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(6 keto-PGF1alpha/20:2(11Z,14Z)), in particular, consists of one chain of 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(20:2(11Z,14Z)/TXB2)

{[(1S,6R,12Z,15S,16S,20R,21R,22R,23R,24S,25R)-3,16,18,21,23,24,25-heptahydroxy-20-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-{[(11Z,14Z)-icosa-11,14-dienoyloxy]methyl}-3,8-dioxo-2,4,7,19-tetraoxa-3lambda5-phosphabicyclo[13.7.3]pentacos-12-en-22-yl]oxy}phosphonic acid

C49H86O20P2 (1056.5187415999999)


PIP(20:2(11Z,14Z)/TXB2) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:2(11Z,14Z)/TXB2), in particular, consists of one chain of 11Z,14Z-eicosadienoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(TXB2/20:2(11Z,14Z))

{[(1S,6R,13Z,16S,17S,21R,22R,23R,24R,25S,26R)-3,17,19,22,24,25,26-heptahydroxy-21-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-[(11Z,14Z)-icosa-11,14-dienoyloxy]-3,9-dioxo-2,4,8,20-tetraoxa-3lambda5-phosphabicyclo[14.7.3]hexacos-13-en-23-yl]oxy}phosphonic acid

C49H86O20P2 (1056.5187415999999)


PIP(TXB2/20:2(11Z,14Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(TXB2/20:2(11Z,14Z)), in particular, consists of one chain of Thromboxane B2 at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   
   
   
   
   

3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide

NCGC00385300-01!3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide

C49H76N12O14 (1056.5603676)


   
   

(3beta,21beta,22alpha)-3-(3-O-angeloyl-beta-D-glucopyranosyloxy)-21,22-dihydroxy-28-beta-sophorosyloxy-16-oxoolean-12-ene|terminaliaside A

(3beta,21beta,22alpha)-3-(3-O-angeloyl-beta-D-glucopyranosyloxy)-21,22-dihydroxy-28-beta-sophorosyloxy-16-oxoolean-12-ene|terminaliaside A

C53H84O21 (1056.5504814)


   
   
   

cynaforrogenin A 3-O-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-oleandropyranoside|cynaforroside G

cynaforrogenin A 3-O-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-oleandropyranoside|cynaforroside G

C52H80O22 (1056.514098)


   

alternoside XIV|chichipegenin 22-O-tigloyl-3-O-beta-D-glucopyranosyl(1->3)-beta-D-glucuronopyranosyl-28-O-beta-D-glucopyranoside

alternoside XIV|chichipegenin 22-O-tigloyl-3-O-beta-D-glucopyranosyl(1->3)-beta-D-glucuronopyranosyl-28-O-beta-D-glucopyranoside

C53H84O21 (1056.5504814)


   

11(S)-convolvulinolic acid 11-O-beta-D-glucopyranosyl-(1->3)-O-[4-O-2S-methylbutyryl-alpha-L-rhamnopyranosyl-(1->4)-]-O-alpha-L-rhamnopyranosyl-(1->4)-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-fucopyranoside-1,3-ester|quamoclin V

11(S)-convolvulinolic acid 11-O-beta-D-glucopyranosyl-(1->3)-O-[4-O-2S-methylbutyryl-alpha-L-rhamnopyranosyl-(1->4)-]-O-alpha-L-rhamnopyranosyl-(1->4)-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-fucopyranoside-1,3-ester|quamoclin V

C49H84O24 (1056.5352264)


   

26-O-beta-D-glucopyranosyl-22alpha-methoxyfurosta-5,25(27)-diene-1beta,3beta,26-triol 1-O-alpha-L-rhamnopyranosyl-(1->2)-3-acetyl-4-[(2S,3S )-2-hydroxy-3-methylpentanoyl]-alpha-L-arabinopyranoside

26-O-beta-D-glucopyranosyl-22alpha-methoxyfurosta-5,25(27)-diene-1beta,3beta,26-triol 1-O-alpha-L-rhamnopyranosyl-(1->2)-3-acetyl-4-[(2S,3S )-2-hydroxy-3-methylpentanoyl]-alpha-L-arabinopyranoside

C53H84O21 (1056.5504814)


   
   

cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoanteisopentadecanoic acid)|maribasin B

cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoanteisopentadecanoic acid)|maribasin B

C49H76N12O14 (1056.5603676)


   
   

3-O-beta-D-galactopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 28-O-angeloyl-A1-barrigenol

3-O-beta-D-galactopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 28-O-angeloyl-A1-barrigenol

C53H84O21 (1056.5504814)


   

cynaforrogenin A 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->4)-alpha-L-cymaropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-oleandropyranoside|cynaforroside P

cynaforrogenin A 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->4)-alpha-L-cymaropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-oleandropyranoside|cynaforroside P

C52H80O22 (1056.514098)


   

3-O-beta-D-glucopyranosyl-(1->2)-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucuronopyranosyl-22-O-beta,beta-dimethylacryloyl-A1-barrigenol

3-O-beta-D-glucopyranosyl-(1->2)-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucuronopyranosyl-22-O-beta,beta-dimethylacryloyl-A1-barrigenol

C53H84O21 (1056.5504814)


   

cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoisopentadecanoic acid)|maribasin A

cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoisopentadecanoic acid)|maribasin A

C49H76N12O14 (1056.5603676)


   

3-O-beta-D-glucopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 22-O-angeloyl-A1-barrigenol

3-O-beta-D-glucopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 22-O-angeloyl-A1-barrigenol

C53H84O21 (1056.5504814)


   

3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide)

Maribasin B (NCGC00385300-01!3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide)

C49H76N12O14 (1056.5603676)


   

barium dinonylnaphthalenesulfonate

barium dinonylnaphthalenesulfonate

C56H86BaO6S2 (1056.4917856)


   
   
   
   
   
   
   
   

MART-1 (26-35) (human) (TFA)

MART-1 (26-35) (human) (TFA)

C44H75F3N10O16 (1056.5314346)


MART-1 (26-35) (human) TFA is amino acid residue 26 to 35 of MART-1 protein.

   

(11r)-11-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4s,5r,6r)-3-{[(2s,3r,4r,5r,6s)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-{[(2s,3s)-3-hydroxy-2-methylbutanoyl]oxy}-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyl-3-{[(2s)-2-methylbutanoyl]oxy}oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}hexadecanoic acid

(11r)-11-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4s,5r,6r)-3-{[(2s,3r,4r,5r,6s)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-{[(2s,3s)-3-hydroxy-2-methylbutanoyl]oxy}-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyl-3-{[(2s)-2-methylbutanoyl]oxy}oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}hexadecanoic acid

C50H88O23 (1056.5716098)


   

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)


   

2-{[8a-({[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-9,10-dihydroxy-4,4,6a,6b,11,11,14b-heptamethyl-8-oxo-2,3,4a,5,6,7,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl 2-methylbut-2-enoate

2-{[8a-({[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-9,10-dihydroxy-4,4,6a,6b,11,11,14b-heptamethyl-8-oxo-2,3,4a,5,6,7,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl 2-methylbut-2-enoate

C53H84O21 (1056.5504814)


   

3-[1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

3-[1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)


   

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9s)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9s)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)


   

(11r)-11-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4s,5s,6r)-3-{[(2s,3r,4r,5r,6s)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(3-hydroxy-2-methylbutanoyl)oxy]-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyl-3-[(2-methylbutanoyl)oxy]oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}hexadecanoic acid

(11r)-11-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4s,5s,6r)-3-{[(2s,3r,4r,5r,6s)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(3-hydroxy-2-methylbutanoyl)oxy]-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyl-3-[(2-methylbutanoyl)oxy]oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}hexadecanoic acid

C50H88O23 (1056.5716098)


   

(1r,3ar,3bs,7s,9ar,9br,11r,11as)-1-acetyl-3a,3b-dihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-3-phenylprop-2-enoate

(1r,3ar,3bs,7s,9ar,9br,11r,11as)-1-acetyl-3a,3b-dihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-3-phenylprop-2-enoate

C57H84O18 (1056.5657364)


   

3-[(3r,7r,10r,13r,16s,19s,22s,27ar)-1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-[(9s)-9-methylundecyl]-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

3-[(3r,7r,10r,13r,16s,19s,22s,27ar)-1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-[(9s)-9-methylundecyl]-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)


   

(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-benzyl-8-[(2s)-butan-2-yl]-6,13,16,21-tetrahydroxy-15-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}pentanediimidic acid

(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-benzyl-8-[(2s)-butan-2-yl]-6,13,16,21-tetrahydroxy-15-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}pentanediimidic acid

C54H72N8O14 (1056.5167732)


   

3-[1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-(9-methylundecyl)-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

3-[1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-(9-methylundecyl)-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)


   

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9r)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9r)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)